iShares MSCI Singapore ETF vs Medtronic PLC — how do they compare? iShares MSCI Singapore ETF trades at $31.84, while Medtronic PLC trades at $83.4 (market cap $103.01B). The key difference: Medtronic PLC pays a 3.58% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| EWS | MDT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $105.35 |
52-Week Low | $26.47 | $73.75 |
Market Cap | — | $103.01B |
Enterprise Value | — | $121.75B |
Dividend Yield | — | 3.58% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medtronic (MDT) trades at $83.19, up 4.91% over the past 24 hours, with a technical outlook that is bearish based on moving averages but supported by neutral oscillators. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.55 surpassing the $1.54 estimate. Revenue grew to $33.54 billion in 2025, and the company maintains strong profitability with a net income margin of 13.2%. Recent corporate actions include a $0.72 dividend payment scheduled for July 2026.
The outlook for MDT is positive, supported by robust fundamentals, a favorable analyst consensus with a $97.50 price target, and a dividend aristocrat status. Key risks include increasing debt levels and competitive pressures in the medical device sector. The stock presents a long-term opportunity for growth and income, though near-term technical weakness may persist.
Trailing returns across standard periods
Latest headlines on both assets
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →